<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833582</url>
  </required_header>
  <id_info>
    <org_study_id>ZN-c3-003</org_study_id>
    <nct_id>NCT04833582</nct_id>
  </id_info>
  <brief_title>A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma</brief_title>
  <official_title>A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination With Gemcitabine in Adult and Pediatric Subjects With Relapsed or Refractory Osteosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>K-Group Beta</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>K-Group Beta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/2 study of ZN-c3 in combination with gemcitabine in adult and pediatric&#xD;
      subjects with relapsed or refractory osteosarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1/2 dose escalation and dose expansion study, evaluating the clinical&#xD;
      activity and safety, pharmacodynamics, and pharmacokinetics of ZN-c3 in combination with&#xD;
      gemcitabine in relapsed or refractory osteosarcoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLT) in DLT evaluable subjects and the incidence and severity of adverse events.</measure>
    <time_frame>Through Cycle 1 (21 days) Phase 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival (EFS) at 18 weeks per RECIST (Response Evaluation Criteria in Solid Tumors) Guideline version 1.1.</measure>
    <time_frame>During phase 2, at 18 weeks</time_frame>
    <description>EFS at 18 weeks is defined as time from study enrollment until date of disease progression, or detection of disease at a previously uninvolved site, or date of death of the subjects at 18 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS) per RECIST Guideline version 1.1.</measure>
    <time_frame>At 12 months</time_frame>
    <description>EFS is defined as time from study enrollment until date of last contact, date of disease progression, or detection of disease at a previously uninvolved site, or date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival (OS) and OS at 12 months per RECIST Guideline version 1.1.</measure>
    <time_frame>At 12 months</time_frame>
    <description>OS is defined as the time from date of first dosing until the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency and severity of adverse events (AEs) and laboratory abnormalities per the National Cancer Institute Common Terminology (NCI CTCAE) version 5.0.lities.</measure>
    <time_frame>Through completion, approximately 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics (PK) maximum concentration (Cmax).</measure>
    <time_frame>Through completion, approximately 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK time to maximum concentration (Tmax).</measure>
    <time_frame>Through completion, approximately 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus timepoint curve (AUC last).</measure>
    <time_frame>Through completion, approximately 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the plasma PK concentration.</measure>
    <time_frame>Through completion, approximately 42 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>Combination ZN-c3 with Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZN-c3</intervention_name>
    <description>ZN-c3 is an investigational drug.</description>
    <arm_group_label>Combination ZN-c3 with Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine is an approved drug</description>
    <arm_group_label>Combination ZN-c3 with Gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 12 years at the time of informed consent&#xD;
&#xD;
          -  Bodyweight ≥ 40 kg&#xD;
&#xD;
          -  Histologically documented relapsed or metastatic osteosarcoma.&#xD;
&#xD;
          -  Must have measurable disease according to RECIST Guideline version 1.1 criteria.&#xD;
&#xD;
          -  Adequate hematologic and organ function.&#xD;
&#xD;
          -  Female subjects of childbearing potential and male subjects must agree to use an&#xD;
             effective method of contraception per institutional standard prior to the first dose&#xD;
             and for 6 months after study treatment discontinuation.&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plan, laboratory&#xD;
             tests, and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unresolved toxicity of Grade &gt;1 attributed to prior therapies (excluding: Grade ≤2&#xD;
             neuropathy, alopecia, or skin pigmentation)&#xD;
&#xD;
          -  Prior therapy with a WEE1 inhibitor&#xD;
&#xD;
          -  A serious illness or medical condition(s).&#xD;
&#xD;
          -  Pregnant or lactating females. Females of childbearing potential with a positive serum&#xD;
             pregnancy test &lt;14 days to Day 1.&#xD;
&#xD;
          -  Subjects with active (uncontrolled, metastatic) second malignancies or requiring&#xD;
             therapy.&#xD;
&#xD;
          -  12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of&#xD;
             &gt;470 ms, except for subjects with atrioventricular pacemakers or other conditions&#xD;
             (e.g., right bundle branch block) that render the QT measurement invalid.&#xD;
&#xD;
          -  History or current evidence of congenital or family history of long QT syndrome or&#xD;
             Torsades de Pointes (TdP).&#xD;
&#xD;
          -  Taking medications with a known risk of TdP.&#xD;
&#xD;
          -  Administration of strong and moderate CYP3A4 inhibitors/inducers and strong and&#xD;
             moderate P-gp inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Project Director</last_name>
    <phone>(858) 263-4333</phone>
    <email>info@zenopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 0106</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 0124</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 0195</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 0104</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 0105</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 0107</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 0123</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 0103</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 0122</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

